Clinical trials · Los Angeles, CA
Refractory Hodgkin Lymphoma clinical trials in Los Angeles
We’re tracking 36 recruiting refractory hodgkin lymphoma studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Los Angeles, CaliforniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Los Angeles, CaliforniaAges 1–30 - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Los Angeles, CaliforniaAges 18 years+ - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Los Angeles, CaliforniaAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Los Angeles, CaliforniaAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Los Angeles, CaliforniaAges 13–90 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Los Angeles, CaliforniaAges 18 years+ - NCT07439653RecruitingPhase 1/Phase 2
Testing TORL-5-700 for advanced lymphoma
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
Santa Monica, CaliforniaAges 18 years+ - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Torrance, CaliforniaAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Duarte, CaliforniaAges 18 years+ - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Duarte, CaliforniaAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT04561206RecruitingPhase 2
Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Duarte, CaliforniaAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+
Hear when a new Refractory Hodgkin Lymphoma trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
Refractory Hodgkin Lymphoma trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting refractory hodgkin lymphoma studies listed above.
- City of Hope Comprehensive Cancer Center · 14 studies
- Cedars-Sinai Medical Center · 3 studies
- University of California, Los Angeles (UCLA) · 3 studies
- Valkyrie Clinical Trials · 3 studies
- Children's Hospital Los Angeles · 2 studies
- Providence Medical Foundation · 2 studies
- The Lundquist Institute at Harbor-UCLA Medical Center · 2 studies
- University of California, Irvine · 2 studies
What taking part in a refractory hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory hodgkin lymphoma studies in California.
Common questions
- Are there refractory hodgkin lymphoma clinical trials near Los Angeles?
- Yes. We're currently tracking 36 recruiting refractory hodgkin lymphoma studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory hodgkin lymphoma study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory hodgkin lymphoma studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.